These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24486637)

  • 1. The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial.
    Amundsen CL; Richter HE; Menefee S; Vasavada S; Rahn DD; Kenton K; Harvie HS; Wallace D; Meikle S
    Contemp Clin Trials; 2014 Mar; 37(2):272-83. PubMed ID: 24486637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
    Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
    J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.
    Amundsen CL; Richter HE; Menefee SA; Komesu YM; Arya LA; Gregory WT; Myers DL; Zyczynski HM; Vasavada S; Nolen TL; Wallace D; Meikle SF
    JAMA; 2016 Oct; 316(13):1366-1374. PubMed ID: 27701661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications.
    Komesu YM; Amundsen CL; Richter HE; Erickson SW; Ackenbom MF; Andy UU; Sung VW; Albo M; Gregory WT; Paraiso MF; Wallace D;
    Am J Obstet Gynecol; 2018 Jan; 218(1):111.e1-111.e9. PubMed ID: 29031894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient preferences for treating refractory overactive bladder in the UK.
    Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
    Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
    Andy UU; Amundsen CL; Honeycutt E; Markland AD; Dunivan G; Dyer KY; Korbly NB; Bradley M; Vasavada S; Mazloomdoost D; Thomas S;
    Am J Obstet Gynecol; 2019 Nov; 221(5):513.e1-513.e15. PubMed ID: 31211964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
    Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
    J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.
    Visco AG; Brubaker L; Richter HE; Nygaard I; Paraiso MF; Menefee SA; Schaffer J; Wei J; Chai T; Janz N; Spino C; Meikle S;
    Contemp Clin Trials; 2012 Jan; 33(1):184-96. PubMed ID: 22008247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence.
    Richter HE; Amundsen CL; Erickson SW; Jelovsek JE; Komesu Y; Chermansky C; Harvie HS; Albo M; Myers D; Gregory WT; Wallace D;
    J Urol; 2017 Oct; 198(4):890-896. PubMed ID: 28501541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.
    Abdel-Fattah M; Chapple C; Guerrero K; Dixon S; Cotterill N; Ward K; Hashim H; Monga A; Brown K; Drake MJ; Gammie A; Mostafa A; Bladder Health UK; Breeman S; Cooper D; MacLennan G; Norrie J
    Trials; 2021 Oct; 22(1):745. PubMed ID: 34702331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seminal papers in urology: two-year outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a Randomized Trial.
    Abd Wahab HHB; O'Callaghan M
    BMC Urol; 2024 Jan; 24(1):16. PubMed ID: 38229041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Fluctuations in Treatment Response After OnabotulinumToxinA and Sacral Neuromodulation for Refractory Urgency Incontinence.
    Hendrickson WK; Zhang C; Jelovsek JE; Nygaard IE; Presson AP
    J Urol; 2024 Jan; 211(1):134-143. PubMed ID: 37871326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
    Chuang YC; Kaufmann JH; Chancellor DD; Chancellor MB; Kuo HC
    J Urol; 2014 Dec; 192(6):1743-9. PubMed ID: 25046622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA-A secondary analysis.
    Guirguis Hanna M; Bradley M; Zyczynski H; Wang L; Giugale L
    Neurourol Urodyn; 2023 Aug; 42(6):1238-1244. PubMed ID: 37086398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System.
    Bertapelle MP; Vottero M; Popolo GD; Mencarini M; Ostardo E; Spinelli M; Giannantoni A; D'Ausilio A
    World J Urol; 2015 Aug; 33(8):1109-17. PubMed ID: 25218855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
    Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
    Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botox rechallenge-An additional tool in the management of an incompletely emptying bladder and inadequate overactive symptom control following sacral neuromodulation.
    Timm B; Jayarajan J; Chan G; Bolton D
    Low Urin Tract Symptoms; 2021 Jan; 13(1):194-197. PubMed ID: 32548938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actual treatment of overactive bladder and urge urinary incontinence.
    Cornu JN
    Minerva Urol Nefrol; 2013 Mar; 65(1):21-35. PubMed ID: 23538308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.